tradingkey.logo

Dare Bioscience Inc

DARE
View Detailed Chart
2.170USD
+0.010+0.46%
Close 12/24, 16:00ETQuotes delayed by 15 min
30.23MMarket Cap
LossP/E TTM

Dare Bioscience Inc

2.170
+0.010+0.46%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.46%

5 Days

-4.82%

1 Month

+22.60%

6 Months

-17.80%

Year to Date

-30.45%

1 Year

-32.19%

View Detailed Chart

TradingKey Stock Score of Dare Bioscience Inc

Currency: USD Updated: 2025-12-24

Key Insights

Dare Bioscience Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 93/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.75.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dare Bioscience Inc's Score

Industry at a Glance

Industry Ranking
93 / 158
Overall Ranking
255 / 4562
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.750
Target Price
+484.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dare Bioscience Inc Highlights

StrengthsRisks
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78K.
Fairly Valued
The company’s latest PE is -1.19, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 394.90K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.

Dare Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dare Bioscience Inc Info

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Ticker SymbolDARE
CompanyDare Bioscience Inc
CEOJohnson (Sabrina Martucci)
Websitehttps://www.darebioscience.com/

FAQs

What is the current price of Dare Bioscience Inc (DARE)?

The current price of Dare Bioscience Inc (DARE) is 2.170.

What is the symbol of Dare Bioscience Inc?

The ticker symbol of Dare Bioscience Inc is DARE.

What is the 52-week high of Dare Bioscience Inc?

The 52-week high of Dare Bioscience Inc is 9.190.

What is the 52-week low of Dare Bioscience Inc?

The 52-week low of Dare Bioscience Inc is 1.610.

What is the market capitalization of Dare Bioscience Inc?

The market capitalization of Dare Bioscience Inc is 30.23M.

What is the net income of Dare Bioscience Inc?

The net income of Dare Bioscience Inc is -4.05M.

Is Dare Bioscience Inc (DARE) currently rated as Buy, Hold, or Sell?

According to analysts, Dare Bioscience Inc (DARE) has an overall rating of Buy, with a price target of 10.750.

What is the Earnings Per Share (EPS TTM) of Dare Bioscience Inc (DARE)?

The Earnings Per Share (EPS TTM) of Dare Bioscience Inc (DARE) is -1.824.
KeyAI